IL18 and tuberculosis: In our study, we used the recombinant M. bovis BCG strain secreting murine interleukin (IL)-18 (rBCG/IL-18) as a prototype of a modified BCG anti-TB vaccine that could potentially be more effective than wild-type BCG in driving an immune response that is able to prevent the development of active TB.